Proactive Investors - Run By Investors For Investors

Faron Pharma updates on Clevegen development as partner discussions advance

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), updates Proactive London's Andrew Scott following the release of their 2018 results.

The company's main focus recently has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.

Meanwhile a second phase III study is now planned for its Traumakine treatment, subject to approval from regulators and external funding.

 
Meet White Rock Minerals Ltd and Meteoric Resources NL at our event, Melbourne , 27 August 2019. Register here »
View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use